>
Zomedica logo

ZOM - Zomedica Share Price

$0.515 -0.0  -2.6%

Last Trade - 26/10/21

Sector
Healthcare
Size
Mid Cap
Market Cap £374.2m
Enterprise Value £174.5m
Revenue £21.7k
Position in Universe 3680th / 7274
Bullish
Bearish
Unlock ZOM Revenue
Momentum
Relative Strength (%)
1m -0.30%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -81.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 4.43 15.2
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2021, Zomedica Corprevenues increased from $0K to $30K. Net loss increased 13%to $8.7M. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Higher net loss reflects Other income (loss)decrease from $6K (income) to $22K (expense), Interestexpense increase from $1K to $6K (expense), Foreignexchange loss (gain) decrease from $1K (income) to $0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ZOM Revenue Unlock ZOM Revenue

Net Income

ZOM Net Income Unlock ZOM Revenue

Normalised EPS

ZOM Normalised EPS Unlock ZOM Revenue

PE Ratio Range

ZOM PE Ratio Range Unlock ZOM Revenue

Dividend Yield Range

ZOM Dividend Yield Range Unlock ZOM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ZOM EPS Forecasts Unlock ZOM Revenue
Profile Summary

Zomedica Corp. is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. The Company is developing point-of-care diagnostic platform, which is based on miniaturized laser-based Raman spectroscopy technology and is designed to detect pathogens in companion animals. It offers TRUFORMA is a diagnostic biosensor platform and the first five assays for the detection of thyroid disorders in dogs and cats and adrenal disorders in dogs. The TRUFORMA platform uses bulk acoustic wave (BAW) technology to provide a non-optical and fluorescence free detection system for use at the point-of-care. The TRUFORMA also offers complete control over the testing process from start to finish, with sensitive and specific immunoassays that allow veterinarians to make clinical decisions.

Directors
Last Annual December 31st, 2020
Last Interim June 30th, 2021
Incorporated January 7, 2013
Public Since October 28, 2013
No. of Shareholders: n/a
No. of Employees: 19
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NYSE MKT
Shares in Issue 979,728,168
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ZOM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ZOM
Upcoming Events for ZOM
Wednesday 10th November, 2021 Estimate
Q3 2021 Zomedica Corp Earnings Release
Thursday 24th February, 2022 Estimate
Q4 2021 Zomedica Corp Earnings Release
Frequently Asked Questions for Zomedica
What is the Zomedica share price?

As of 26/10/21, shares in Zomedica are trading at $0.515, giving the company a market capitalisation of £374.2m. This share price information is delayed by 15 minutes.

How has the Zomedica share price performed this year?

Shares in Zomedica are currently trading at $0.515 and the price has moved by 0.597k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Zomedica price has moved by 0.421k% over the past year.

What are the analyst and broker recommendations for Zomedica?

Of the analysts with advisory recommendations for Zomedica, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Zomedica is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Zomedica next release its financial results?

Zomedica is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the Zomedica dividend yield?

Zomedica does not currently pay a dividend.

Does Zomedica pay a dividend?

Zomedica does not currently pay a dividend.

When does Zomedica next pay dividends?

Zomedica does not currently pay a dividend.

How do I buy Zomedica shares?

To buy shares in Zomedica you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Zomedica?

Shares in Zomedica are currently trading at $0.515, giving the company a market capitalisation of £374.2m.

Where are Zomedica shares listed? Where are Zomedica shares listed?

Here are the trading details for Zomedica:

Country of listing: United States
Exchange: ASQ
Ticker Symbol: ZOM
What kind of share is Zomedica?

Based on an overall assessment of its quality, value and momentum, Zomedica is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Zomedica share price forecast 2021?

Shares in Zomedica are currently priced at $0.515. At that level they are trading at 0.128% discount to the analyst consensus target price of 0.00.

Analysts covering Zomedica currently have a consensus Earnings Per Share (EPS) forecast of -0.01 for the next financial year.

How can I tell whether the Zomedica share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zomedica. Over the past six months, the relative strength of its shares against the market has been -54.69%. At the current price of $0.515, shares in Zomedica are trading at -48.14% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Zomedica PE Ratio?

We were not able to find PE ratio data for Zomedica.

Who are the key directors of Zomedica?

Zomedica's management team is headed by:

Rodney Williams - IND
Jeffrey Rowe - NEC
Stephanie Morley - COO
Bruk Herbst - OTH
Johnny Powers - IND
Robert Cohen - DRC
Christopher MacLeod - IND
Ann Cotter - CFO
Sean Whelan - DRC
Larry Heaton - CEO
Who are the major shareholders of Zomedica?

Here are the top five shareholders of Zomedica based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 4.34% (42.5m shares)
Vanguard Total Stock Market Index Fund Mutual Fund
Percentage owned: 2.67% (26.2m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 1.87% (18.4m shares)
SPDR S&P Health Care Equipment ETF Mutual Fund
Percentage owned: 1.76% (17.2m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 1.71% (16.7m shares)
Similar to ZOM
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.